|
The said drug is equivalent to reference listed drug, Zinc Sulfate Injection. The drug will be manufactured at the group's formulation manufacturing facility at Jarod. Zinc Sulfate Injection is indicated in adult and paediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Zinc Sulfate Injection and Pharmacy Bulk Package Vials had annual sales of $ 17.1 million in the United States (IQVIA MAT June 2023).
As on 31 June 2023, the group now has 377 approvals and has so far filed over 444 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Zydus Lifesciences reported 109.7% surge in net profit to Rs 1,086.9 crore in Q1 FY24 as compared with Rs 518.3 crore posted in Q1 FY23. Revenue from operations jumped 29.6% to Rs 5,139.6 crore during the quarter as compared with Rs 3,964.4 crore recorded in same quarter last year.
The scrip rose 0.07% to Rs 645.75 on the BSE.
|